Abetes was induced by intraperitoneal injection of streptozotocin into 8-week-old C57BL/6 male mice. At eight weeks right after the induction of diabetes, the animals have been distributed into 7 groups: manage non-diabetic mice and diabetic mice receiving two successive intracavernous injections of HEPES-buffered saline (HBS, days -3 and 0; 20 L) or ESC-JOURNAL OF EXTRACELLULAR VESICLESderived EV-mimetic NVs (ESC-NVs, days -3 and 0; 0.1 g, 0.five g, 1 g, two g, or five g in 20 L of HBS, respectively). Two week soon after therapy, we measured erectile function by electrical stimulation of the cavernous nerve. The penis was then harvested for histological and biochemical Nav1.4 web research. We also examined the effects of ESC-Exo in key cultured mouse cavernous endothelial cells (MCEC) and pericytes (MCP) in vitro; and in cultured aortic ring and big pelvic ganglion (MPG) ex vivo. Results: Intracavernous injections of ESC-NVs significantly improved erectile function in diabetic mice, which reached as much as 90 of manage values. ESC-NVs induced significant restoration of cavernous contents of endothelial cells, smooth muscle cells, pericytes, and neuronal cells in diabetic condition. Furthermore, ESCNVs promoted micro-vascular sprouting from aortic ring and accelerated tube formation in principal cultured MCEC and MCP mono-culture or co-culture technique in vitro. Summary/Conclusion: ESC-NVs successfully restored erectile function through enhanced cavernous angiogenesis and neural regeneration in diabetic mice. It will be a superior approach to make use of ESC-NVs than ESCs for the treatment of retractable erectile dysfunction while it remains to be solved for future clinical application of ESCs.PT12.Human adipose tissue-derived mesenchymal stem cell exosomes for the therapy of liver fibrosis Sol Shin, Soyoung Son, Gyeongtaek Lim, Seunglee Kwon and Jaehyung Parkaof A-exo was determined by BCA assay. The SIRT1 Species impact of A-Exo on the expression amount of -SMA was evaluated by IF analysis. Mice were received thioacetamide intraperitoneally. Fluorescently labelled A-exo was administered to mice and whole-body fluorescence was observed in order to evaluate the in vivo distribution. The therapeutic efficacy of A-exo was determined by measuring the level of ALT, ALP, TBIL and TP in blood of mice. A-exo was injected intravenously 3 instances and blood was collected just after final injection. Final results: When hepatic stellate cells have been activated with TGF-1, the expression amount of -SMA was significantly increased. Whilst, the level was remarkably decreased depending on the therapy concentration of A-Exo. A-exo remedy substantially decreased expression mRNA of pro-fibrogenic marker: -SMA, Collagen I and MMP-2. Right after systemic administration of exosome, a substantial accumulation of A-Exo at liver was observed in both the normal and mice model of liver fibrosis. Moreover, liver function of A-exo treated group was restored to standard. These results showed A-exo had the high therapeutic efficacy. Summary/Conclusion: In this study, we investigate the prospective of stem cell-derived exosome as the new therapeutic strategy for liver fibrosis remedy. Aexo has similar bioactive capacity to its origin cell, mesenchymal stem cell. The helpful impact of A-exo was confirmed in vitro and in vivo tests. The superior therapeutic efficacy was displayed in A-exo treated mouse group.PT12.HucMSC exosome confer protection against ultraviolet radiation induced acute photodamage via modulation of SIRT1 pathway Peipei.
